Potential cost-savings from the use of the biosimilars filgrastim, infliximab and insulin glargine in Canada: a retrospective analysis

Table 1 Description of Canadian Drugstore and Hospital (CDH) purchases and potential dollar savings from July 2016 to June 2018 for all provinces

	CDH Purchases	Units Purchased	Price Per Unit	Average Discounted Price (%)	Average Realized Savings through use of biosimilar	Unrealized Savings	Overall savings realized (%)
Lantus®	$ 141,135,286	7,328,068	$ 19.26	$ 4.07 (21.1%)	$ 2,519,961	$29,825,236	7.8%
Basaglar®	$ 9,402,061	619,155	$ 15.19	$ 4.07 (21.1%)	$ 2,519,961	$29,825,236	7.8%
Neupogen®	$ 204,152,590	1,033,508	$ 197.53	$ 35.17 (17.8%)	$ 13,443,873	$36,348,476	27.0%
Grastofil®	$ 62,061,576	382,254	$ 162.36	$ 35.17 (17.8%)	$ 13,443,873	$36,348,476	27.0%
Remicade®	$ 2,192,819,808	2,190,467	$ 1001.07	$ 448.53 (44.8%)	$ 30,199,524	$982,490,164	3.0%
Inflectra®	$ 37,202,503	67,330	$ 552.54	$ 448.53 (44.8%)	$ 30,199,524	$982,490,164	3.0%
TOTAL					$ 46,163,358	$1,048,663,876	4.2%

All dollar figures are in Canadian dollars
Estimates of realized and unrealized savings are based on the average discounted price amongst all provinces
Unrealized savings is calculated as the average price difference between the originator and biosimilar amongst all provinces, multiplied by the number of originator units sold

ISSN: 1472-6963